TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01212991

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo, administered as four capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
Study: NCT01523158

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Allergovit grass or birch
Description: subcutaneous injection of immunotherapy once weekly for 7 weeks prior to birch pollen season.
Study: NCT04414904

Intervention type: OTHER
Intervention: Exposure: Covid-19 infection
Description: Previous history of COVID-19 infection.
Study: NCT04744402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Chondrocyte Implantation (CartiLife®)
Description: CartiLife consists of small beads (1 mm in diameter) in suspension, developed from pellet culture of autologous costal chondrocytes after multiplication. The beads are implanted in an injective manner with fibrin glue through minimal arthrotomy. The dose depends on the size (volume) of the defect, recommended dose is 480 pellets/cm\^3 defect
Study: NCT01926977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.5mg
Description: Patient will receive intravitreal injection of Ranibizumab 0.5mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept 2.0mg
Description: Patients will receive intravitreal injection of Aflibercept 2.0mg.
Study: NCT01177696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapeutic intervention
Description: A psychotherapeutic intervention will be 8 sessions of 90 minutes in a pilot study groups. This intervention has been initially developed for family caregivers of patients with dementia.
Study: NCT02817282

Intervention type: OTHER
Group type: OTHER
Intervention: Hand hygiene implementation strategy
Description: Implementation strategy: Individual oriented activities. Education based on the different determinants influencing HCWs' behavior. Reminders for supporting the actual performance of HH; by distributing posters. Performance feedback for awareness. Goal setting will be encouraged and the feedback will be used to help HCWs evaluate their success and determine how they could best adapt their behavior in order to reach their goal. Organisational oriented activities. Products and facilities: The physical environment will be adapted by improving the availability of hand based hand rub. Team-oriented activities; The social environment will be adapted by training at a group and individual level, to improve social and descriptive norms. Positive role models will be stimulated through this training.
Study: NCT03166865

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical-cord mesenchymal stromal cells (UC-MSCs)
Description: Allogeneic UC-MSCs 1 x 10\~7 diluted on 5 mL of Platelet Rich Plasma

Intervention type: OTHER
Group type: OTHER
Intervention: Hyaluronic acid
Description: intra-articular injection of Hyaluronic Acid
Study: NCT00702585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 36286
Description: Org 36286 single-dose subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 36286
Description: Org 36286 single-dose subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 36286
Description: Org 36286 single-dose subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 36286
Description: Org 36286 single-dose subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Org 36286 as a single-dose subcutaneous injection
Study: NCT02222454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KLOX BioPhotonic System
Description: KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 16 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for pressure ulcers.
Study: NCT02713191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 1µg/Kg in 100 mL saline intravenously over 10-15 minutes immediately prior to procedure, followed by Dexmedetomidine infusion at 0.6 µg/kg/hour as maintenance dose during entire procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam bolus
Description: Midazolam 2 mg as slow intravenous bolus immediately prior to procedure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline placebo
Description: 100 mL saline infusion over 10-15 minutes immediately prior to procedure
Study: NCT06676761

Intervention type: PROCEDURE
Intervention: nipple sparing mastectomy without reconstruction
Description: nipple sparing mastectomy was conventionally performed with reconstruction. we aim to study the outcomes in the group of patients with Minimal scar mastectomy (MSM) who have nipple sparing mastectomy without reconstruction
Study: NCT01048502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate (Tricor) tablets
Description: One 145 mg tablet taken once daily, in the evening, with food, for 6 to 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo capsules taken twice daily, morning and evening, with food and one placebo gel capsule taken once daily, in the evening, with food, for 6 to 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: 900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: 900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.
Study: NCT02594371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraxol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV paclitaxel
Study: NCT02208115

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal composition - Low versus high GI.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal composition - Low versus high GI.
Study: NCT03808870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBM-BMX softgel capsules
Description: Patients will initially receive NBM-BMX orally once a day at 100 mg per day.
Study: NCT01969474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis capsules given once daily for a month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00465049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRIMARY CLOSRE
Description: SUTURE
Study: NCT01325233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG2
Description: Powder for Injection, 500 mg PG2/500 ml normal saline, tiw, 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 ml normal saline, tiw, 2 weeks
Study: NCT02713191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue midazolam
Description: Rescue boluses of 0.5 mg midazolam, if needed during procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue midazolam
Description: Rescue boluses of 0.5 mg midazolam, if needed during procedure
Study: NCT06390852

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study: NCT00465049

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SECONDARY CLOSURE
Description: ALLOW TO HEAL SPONTANEOUSLY

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SPONTANEOUS HALING
Description: SECONDARY HEALING AFTER I\&D
Study: NCT06390852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT02960659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide (6mg/ml, 3ml ) solution for subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6mg, 1.2mg or 1.8mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 500mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500mg oral tablet
Study: NCT03947086

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (TDCS)- Active
Description: A constant current stimulator (TCT Research Limited) will be used using electrodes of 5 × 5 cm2 embedded in saline (0.9 % NaCl) and application of 1.5 mA current for 20 minutes for 5 consecutive days. The cathode will be positioned in the right supra-orbital region, and while the anode will have the following provision in the left dorsolateral prefrontal cortex (F3).
Study: NCT02713191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 1 µg/kg fentanyl as slow intravenous bolus immediately prior to procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 1 µg/kg fentanyl as slow intravenous bolus immediately prior to procedure
Study: NCT02336412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS reminder
Description: Daily SMS medication reminder
Study: NCT00705120

Intervention type: OTHER
Group type: OTHER
Intervention: Bone Marrow Cell Transplantation
Study: NCT01634321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luphere depot 3.75mg(Leuprolide acetate 3.75mg)
Study: NCT01985633

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell suspension
Description: About 8-10ml of bone marrow would be aspirated under strict aseptic precautions, cell fractionationated with Ficoll sol,centrifuged at 1100rpm for 20-30 mins. Buffy layer will be centrifuged again at 1100 rpm for another 20-30 mins. The pellet thus formed will be suspended in 5ml of culture medium. The nucleated stem cells thus isolated, will be incubated at 37deg.C under 5%CO2 in culture flasks for about 4-6weeks. Those cells adherent to flask removed with 0.05% trypsin-EDTA sol and characterised . Those positive for CD90 and CD105 and negative for CD45 and CD34 will be the mesenchymal stem cells. These will then be expanded to 10×106 for use.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: Twelve patients will be placed in supine position with knee in full extension and under full aseptic precautions 8-10 ml of platelet rich plasma would be injected by lateral approach with an 18-20 G needle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: Twelve patients will be placed in supine position with knee in full extension and under full aseptic precautions 8-10 ml of platelet rich plasma would be injected by lateral approach with an 18-20 G needle.
Study: NCT00840944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: somatropin 0.050 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin
Description: triptorelin 3.75 mg each month
Study: NCT04017442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative Free Morphine
Description: After delivery of the baby patients will receive via the epidural catheter prior to its removal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: After delivery of the baby patients will receive via the epidural catheter prior to its removal.
Study: NCT01879956

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Craft Activities
Description: There is no intervention method used to perform the task.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OGI Method
Description: metacognitive approach to assess executive functions.
Study: NCT01153191

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal saline pressurized irrigation
Description: same

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sub-q gentamicin
Description: 2mg/kg of gentamicin in 20 ml of sterile saline up to max dose of 120mg injected above the abdominal wall fascia- the length of the incision will be marked and injection made with intent being to evenly distribute the volume of injection in the subcutaneous tissues in immediate vicinity of and prior to the initial incision- analogous to the technique employed when using local anesthetic
Study: NCT03408548

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling root planning
Description: Periodontal treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling root planning
Description: Periodontal treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: two lozenge per day containing Bifidobacterium animalis lactis HN019

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two lozenge per day not containing Bifidobacterium animalis lactis HN019
Study: NCT02466321

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inverse/Reverse Shoulder Arthroplasty
Description: Implantation of the Anatomical Shoulder Inverse/Reverse System
Study: NCT01238133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT04260828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100mg
Description: Daily active drug administered orally for 3 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill administered orally for 3 months.
Study: NCT00718757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 5 doses given on Days 6-10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 20 mg/m2/day IV, 10 doses given on Days 1-5, 8-12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/m2/day IV (max 2 mg), 2 doses given on Days 1,8~\* Patients \< 1 year of age or \< 10kg in weight: Vincristine 0.05 mg/kg
Study: NCT02952326

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: XP Endo Finsher as final step of the irrigation protocol
Description: The canals will be thoroughly irrigated using 3ml syringe of 2.5% Sodium hypochlorite between every subsequent instrument. XP Endo finisher is used after the last instrument in preparation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional needle irrigation only
Description: The canals will be thoroughly irrigated using 3ml syringe of 2.5% Sodium hypochlorite between every subsequent instrument.
Study: NCT01760824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequential therapy
Description: Esomeprazole 20mg bid for 10 days, amoxicillin 1g bid for first 5 days, clarithromycin 500mg bid for last 5 days and metronidazole 400mg qid for last 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential therapy
Description: Esomeprazole 20mg bid for 10 days, amoxicillin 1g bid for first 5 days, clarithromycin 500mg bid for last 5 days and metronidazole 400mg qid for last 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadruple therapy
Description: Esomeprazole 20mg bid, metronidazole 400mg qid, bismuth sub citrate 120mg qid and tetracycline 500mg qid, all for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quadruple therapy
Description: Esomeprazole 20mg bid, metronidazole 400mg qid, bismuth sub citrate 120mg qid and tetracycline 500mg qid, all for 10 days
Study: NCT04183699

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Prostate biopsy
Description: MRI-targeted + systematic random prostate biopsy
Study: NCT00254293

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abatacept or Placebo (both as IV & SC Solution)
Description: Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 75 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abatacept or Placebo (both as IV & SC Solution)
Description: Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abatacept or Placebo (both as IV & SC solution)
Description: Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 750 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
Study: NCT03947086

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (TDCS)- Sham
Description: The protocol for participants receiving simulated current is identical, but the device ceases to emit current after 30 seconds of initiation of pacing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Considering that the effects of TDCS are potentiated when applied during the execution of a task (online) (Miniussi, \& Ruzzoli, 2013), in the present study all participants received cognitive training, performed concomitantly with neurostimulation.~Cognitive training consists of two parts: standardized tasks directed to social cognition and activities that stimulate executive functions. The first part consists of tasks contained in a battery of social games (Gao \& Maurer, 2009; Dillon, Kannan, Dean, Spelke, \& Duflo, 2017). While the tasks directed to the executive domain are, namely: running mazes, assembling figures, completing parts of figures and the Super Lynx Memory Game. All participants, regardless of whether they underwent active or simulated stimulation, received cognitive training, respecting the ethical principles of ensuring therapeutic assistance to those involved.
Study: NCT00254293

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abatacept or Placebo (both as IV & SC solution)
Description: Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abatacept or Placebo (both as IV & SC solution)
Description: Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 200 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
Study: NCT03947086

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Training
Description: Considering that the effects of TDCS are potentiated when applied during the execution of a task (online) (Miniussi, \& Ruzzoli, 2013), in the present study all participants received cognitive training, performed concomitantly with neurostimulation.~Cognitive training consists of two parts: standardized tasks directed to social cognition and activities that stimulate executive functions. The first part consists of tasks contained in a battery of social games (Gao \& Maurer, 2009; Dillon, Kannan, Dean, Spelke, \& Duflo, 2017). While the tasks directed to the executive domain are, namely: running mazes, assembling figures, completing parts of figures and the Super Lynx Memory Game. All participants, regardless of whether they underwent active or simulated stimulation, received cognitive training, respecting the ethical principles of ensuring therapeutic assistance to those involved.
Study: NCT04048135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegozafermin
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegozafermin
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegozafermin
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegozafermin
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegozafermin
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegozafermin
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegozafermin
Description: Subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study: NCT00705120

Intervention type: OTHER
Group type: OTHER
Intervention: Bone Marrow Cell Transplantation

Intervention type: RADIATION
Group type: OTHER
Intervention: Irradiation, Total Body

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclosporin

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mesenchymal Stem Cell Transplantation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mesenchymal Stem Cell Transplantation

Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan

Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan
Study: NCT02588066

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ligamentum teres/falciform-plasty
Description: Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
Study: NCT03341000

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISCSS Device
Description: This pilot feasibility study will explore and help determine optimal settings and configuration of the DISCSS™ System with patients that have completed a percutaneous trial with a commercially available SCS trial system within the first 3-5 days of the current study.